AstraZeneca Q3 Revenue Rises 7%, $1.5 Billion Cost-Cutting Plan Lifts Shares Over 5% Pre-Market

TradingKey - On October 30, AstraZeneca (AZN) stock rose over 5% in pre-market trading. The company's third-quarter revenue and earnings both exceeded market expectations, while it reaffirmed its full-year guidance and announced a restructuring plan expected to deliver $1.5 billion in annual benefits, boosting investor confidence in its medium- to long-term growth prospects.

Source: TradingView

At constant exchange rates, AstraZeneca's total third-quarter revenue increased 7% year-over-year to $16.209 billion, exceeding market expectations of approximately $16 billion. Product sales grew 5% to $15.066 billion, while alliance revenue surged 36% to $1.107 billion. Core earnings per share were $2.79, up 19% year-over-year and about 7% above the market expectation of approximately $2.60; reported EPS rose 26% to $2.02.

The oncology business remained the primary growth engine, with third-quarter revenue growing 17% year-over-year to $7.77 billion. Sales of breast cancer drug Enhertu rose 35% to $969 million, and immunotherapy Imfinzi revenue grew 26% to approximately $2 billion, helping the company offset generic competition pressures on mature products. Meanwhile, sales of diabetes drug Farxiga fell 25% to $1.61 billion.

Beyond financial performance, market attention also turned to AstraZeneca's R&D pipeline. CEO Pascal Soriot stated that the company currently has over 180 R&D projects, and a series of clinical trials expected to report results in 2027 has a combined peak annual sales potential exceeding $20 billion. Multiple late-stage R&D assets covering oncology, respiratory diseases, and rare diseases provide support for achieving the company's 2030 revenue targets.

To create room for increased R&D investment, AstraZeneca simultaneously launched a "Reshaping for Sustainable Growth" initiative. The project is expected to be largely completed by the end of 2029, generating approximately $1.5 billion in annual pre-tax run-rate benefits, with funds primarily reinvested into the drug pipeline and new technologies. The company expects one-time restructuring costs of up to approximately $2 billion, though it has not disclosed whether layoffs will be involved or the specific scope of business adjustments.

AstraZeneca reaffirmed its full-year 2026 guidance, expecting total revenue to achieve mid-to-high single-digit growth and core EPS to record low double-digit growth at constant exchange rates, with the core tax rate remaining between 18% and 22%. The company also plans to increase its full-year dividend to $3.30 per share.

Overall, third-quarter results that beat expectations, sustained rapid growth in oncology, and potential clinical catalysts in 2027 collectively supported market sentiment. Although mature drugs face patent and generic competition pressures, and restructuring will bring short-term charges, annual cost benefits of $1.5 billion and pipeline value potential exceeding $20 billion provide AstraZeneca with a clearer path toward future growth.